Breaking News: Transcode Therapeutics Receives Green Light from Safety Review Committee for Phase 1 TTX-MC138 Clinical Trial and Unveils Promising Results from First Cohort!
Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2
No significant safety or dose limiting toxicities reported in Cohort 2
New patients currently being evaluated for eligibility in Cohort 3
PK and PD data from Cohort 1 patients consistent with preclinical and Phase 0 trial results
BOSTON , Dec. 18, 2024 /PRNewswire/ — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) monitoring its Phase 1 clinical trial has unanimously approved opening of the third cohort of patients based on its favorable review of Cohort 2 safety data. The therapeutic candidate being evaluated, TTX-MC138, is TransCode’s lead candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA critical to the emergence and progression of many metastatic cancers.
How will this affect me?
As a potential patient, this news signifies a step forward in the development of innovative therapies for cancer treatment. The approval and promising results from the clinical trial indicate that there may be new treatment options on the horizon that could potentially improve outcomes for cancer patients.
How will this affect the world?
The approval of TTX-MC138 for further evaluation in clinical trials represents a significant advancement in the field of oncology. If successful, this treatment could potentially revolutionize the way metastatic cancers are treated, leading to improved survival rates and quality of life for patients worldwide.
Conclusion:
Transcode Therapeutics’ receipt of approval from the Safety Review Committee for Phase 1 TTX-MC138 clinical trial and the unveiling of promising results from the first cohort marks a significant milestone in the development of RNA therapeutics for cancer treatment. The progress made in this trial has the potential to not only impact individual patients but also have a far-reaching effect on the global fight against cancer.
